SCHEMBL7546104

SCHEMBL7546104

Cc1ccc(CCc2sccc2S(=O)(=O)Cl)cc1.Cc1ccc(CCc2sccc2S(=O)(=O)Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 6/20 0.52
EDNRA P25101 6/20 0.52
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 2/20 0.37
CNR2 P34972 1/20 0.36
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2A6 P11509 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
CA12 O43570 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4631374 1.00 EDNRB (0.52) EDNRBEDNRAMEN1KMT2AALDH1A1
SCHEMBL4631580 0.79 EDNRB (0.47) EDNRBEDNRAMEN1KMT2AALDH1A1
SCHEMBL4630655 0.76 EDNRB (0.54) EDNRBEDNRAMEN1KMT2AALDH1A1
SCHEMBL4631437 0.74 EDNRA (0.57) EDNRBEDNRATAAR1
SCHEMBL11484963 0.68 LMNA (0.36) EDNRAMEN1KMT2AALDH1A1LMNA
SCHEMBL30844611 0.67 HPGD (0.45) MEN1KMT2AALDH1A1LMNACYP1A2
SCHEMBL2772816 0.67 LMNA (0.38) MEN1KMT2AALDH1A1LMNA
SCHEMBL4702032 0.66 KMT2A (0.49) MEN1KMT2AALDH1A1CNR2CYP1A2
SCHEMBL143961 0.66 CYP1A2 (0.68) MEN1KMT2AALDH1A1CYP1A2CYP2A6
SCHEMBL11288839 0.66 CYP1A2 (0.68) MEN1KMT2AALDH1A1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0980369-A1 SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-02-23 EP disclosed
WO-1998049162-A1 SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-11-05 WO disclosed